PDE4 negative allosteric modulator as well as preparation method and application thereof
A novel PDE4D negative allosteric modulator, LS21013A-06, addresses the market gap by providing effective antidepressant treatment with reduced side effects and enhanced enzyme inhibition, suitable for depression, fragile X syndrome, and Alzheimer's disease.
Patent Information
- Application Number
- CN202411255501.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-09-09
AI Technical Summary
There is a lack of effective PDE4D negative allosteric modulators for antidepressant drugs on the market, and existing inhibitors face significant side effects such as nausea and vomiting.
A PDE4 negative allosteric modulator with a new structure, specifically 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetic acid (LS21013A-06), is synthesized through a series of chemical reactions including cycloaddition and hydrolysis of tert-butyl ester, demonstrating high efficacy as a PDE4D negative allosteric modulator.
The synthesized modulator effectively reduces side effects while maintaining therapeutic efficacy for depression, fragile X syndrome, and Alzheimer's disease treatment, with minimal toxicity and improved enzyme inhibition properties.
Smart Images

Figure CN119080709A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and in particular relates to a PDE4 negative allosteric regulator and a preparation method and application thereof. Background Art
[0002] Phosphodiesterase 4 (PDE4) is one of the main hydrolases of the second messenger cyclic adenosine monophosphate (cAMP) in the body. It has four subtypes of AD and is related to neuroinflammation, cognitive memory and mood regulation. Its inhibitors can be used to treat depression, fragile X syndrome and Alzheimer's disease, such as the first-generation classic inhibitor Rolipram. Rolipram was abandoned for further clinical research due to side effects such as nausea and vomiting. Its side effects are related to its PDE4B subtype inhibition, while the negative allosteric modulator of PDE4D (PDE4D NAM) can retain the above therapeutic effects while significantly reducing the above adverse reactions.
[0003] According to the World Health Organization, depression is the fourth largest disease burden in the world, and it is expected that by 2023, depression will become the third largest disease after cardiovascular disease and cancer; the antidepressant market has great potential for development. With the continuous increase in the number of depression patients and the increasing awareness of depression in society, domestic companies have gradually increased their investment in the research and development of antidepressant drugs. The antidepressant market has great potential, and no new target drugs have been approved for marketing in the past two decades.
[0004] PDE4 plays a major role in mediating the occurrence and development of depression and is closely related to memory consolidation. Although the antidepressant effect of PDE4 inhibitors has been confirmed decades ago, the vomiting side effect of traditional inhibitors limits their application. PDE4D negative allosteric modulators such as D159687, BPN14770 and our company's Chlorbipram have no vomiting side effects and are in clinical trials or preclinical stages. However, there are currently no PDE4D negative allosteric modulators (PDE4D NAMs) on the market. Summary of the invention
[0005] The present invention provides a PDE4 negative allosteric modulator and its preparation method and application, aiming to solve the problem that there is no effective PDE4D negative allosteric modulator for antidepressant drugs in the market. The PDE4 negative allosteric modulator obtained by the present invention is a PDE4D negative allosteric modulator with a new structure.
[0006] The technical solution of the present invention is achieved in this way:
[0007] A PDE4 negative allosteric modulator, the structural formula of which is shown in Formula I:
[0008]
[0009] Wherein, X is one of the halogen elements;
[0010] R1 is at least one of CH3, H, CHF2 or CH2CH3 groups;
[0011] R2 is at least one of OH, NH2, NH-IPA, NH-Ethanol, NH-SIPA, NH-S2IPA, NH-OH or NH-R2IPA groups.
[0012] More preferably, X is Cl, R1 is CHF2, and R2 is OH.
[0013] Preferably, the preparation method of the PDE4 negative allosteric modulator comprises the following steps: using 2-(3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)acetonitrile as a raw material, obtaining it through a [3+2] cycloaddition reaction, an NH alkylation reaction of tetrazole, and hydrolysis of tert-butyl ester.
[0014] When X is Cl, R1 is CHF2, and R2 is OH, the preparation method of the PDE4 negative allosteric modulator comprises the following steps:
[0015] S01: Synthesis of 5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazole: 5 mmol of 2-(3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)acetonitrile, 7.5 mmol of trimethylsilyl azide and 15 mL of N,N-dimethylformamide were mixed, heated to 90-110°C for 18-24 hours, cooled to room temperature, added with 7.5 mmol of tetrabutylammonium fluoride and stirred at room temperature; after the reaction was completed, 5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazole was obtained by extraction, washing, drying, decompression evaporation of the solvent and chromatography purification;
[0016] S02: Synthesis of tert-butyl 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetate: 4 mmol of 5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetate, 6 mmol of tert-butyl bromoacetate, 6 mmol of potassium carbonate and 10 mL of N,N-dimethylformamide were mixed. After the reaction, the mixture was extracted, washed, dried, the solvent was evaporated under reduced pressure and purified by chromatography to obtain tert-butyl 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetate.
[0017] S03: Synthesis of 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetic acid: 3 mmol of tert-butyl 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetic acid, 6 mmol of formic acid and 10 mL of tert-butanol and water in a ratio of 4:1 were mixed to obtain a mixed solution. After the reaction and pH adjustment, extraction, washing, drying, solvent removal under reduced pressure and chromatography purification were performed to obtain the PDE4 negative allosteric modulator 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetic acid.
[0018] Preferably, in step S01, the extraction, washing, drying, evaporation of the solvent under reduced pressure and purification by chromatography are specifically: extraction with ethyl acetate, washing with saturated brine, drying with anhydrous sodium sulfate, and evaporation of the solvent under reduced pressure to obtain a crude product, and the crude product is purified by rapid silica gel chromatography using ethyl acetate / petroleum ether = 1:2 (V / V) as an eluent to obtain 5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazole.
[0019] Preferably, in step S02, the reaction is followed by extraction, washing, drying, decompression evaporation of the solvent, and chromatography purification, specifically: after reacting at room temperature for 24 hours, the reaction solution is poured into water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and decompression evaporation of the solvent to obtain a crude product, which is purified by rapid silica gel chromatography using ethyl acetate / petroleum ether = 1:5 (V / V) as an eluent to obtain tert-butyl 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetate.
[0020] Preferably, in step S03, after the reaction and after adjusting the pH, extraction, washing, drying, solvent evaporation under reduced pressure, and chromatography purification are performed, specifically: after reacting at 100° C. for 24 hours, the reaction solution is poured into water, diluted hydrochloric acid is added to adjust the pH to 1, extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is evaporated under reduced pressure to obtain a crude product, and the crude product is purified by rapid silica gel chromatography with methanol / dichloromethane = 1:15 (V / V) as the eluent to obtain a PDE4 negative allosteric modulator.
[0021] The PDE4 negative allosteric regulator prepared above is used in antidepressants, drugs for treating fragile X syndrome and drugs for treating Alzheimer's disease.
[0022] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:
[0023] The present invention prepares a PDE4 negative allosteric modulator, preferably 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetic acid (i.e. LS21013A-06), which has the effect of a negative allosteric modulator of PDE4D through detection and can be used in antidepressant drugs, drugs for treating fragile X syndrome and drugs for treating Alzheimer's disease through performance testing. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 This is the H-NMR detection result of the PDE4 negative allosteric modulator (LS21013A-06) prepared in the example.
[0025] Figure 2 This is a graph showing the HPLC detection results of the PDE4 negative allosteric modulator (LS21013A-06) prepared in the example.
[0026] Figure 3 This is a graph showing the LC-MS detection results of the PDE4 negative allosteric modulator (LS21013A-06) prepared in the example.
[0027] Figure 4 This is the first molecular docking diagram of the PDE4 negative allosteric modulator (LS21013A-06) prepared in the example and PDE4D.
[0028] Figure 5 This is the second molecular docking diagram of the PDE4 negative allosteric modulator (LS21013A-06) prepared in the example and PDE4D; Figure 4 and Figure 5 Use different docking models.
[0029] Figure 6This is the third molecular docking diagram of the PDE4 negative allosteric modulator (LS21013A-06) prepared in the example and BPN14770 with PDE4D; the light blue one is the molecular structure diagram of BPN14770.
[0030] Figure 7 The MTT test results of LS21013A-06 prepared in Example on the survival rate of BV2 cells at concentrations of 2.5 μM, 5 μM, 10 μM, 20 μM and 40 μM, wherein A-06 is the abbreviation of LS21013A-06.
[0031] Figure 8 This is a graph showing the detection results of LS21013A-06 obtained in the example reducing the activation of hippocampal microglia in mice injected with LPS in the lateral ventricle.
[0032] Fig. 9 This is a graph showing the detection results of LS21013A-06 obtained in the example reducing the expression of CD68 in the hippocampal microglia of mice injected with LPS in the lateral ventricle. DETAILED DESCRIPTION
[0033] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0034] In addition, the technical solutions between the various embodiments can be combined with each other, but it must be based on the fact that ordinary technicians in the field can implement it. When the combination of technical solutions is contradictory or cannot be implemented, it should be deemed that such combination of technical solutions does not exist and is not within the scope of protection required by the present invention.
[0035] At present, there is a problem that there is no effective PDE4D negative allosteric modulator for antidepressant drugs on the market. In order to solve the above technical problems, the present invention provides a PDE4 negative allosteric modulator and a preparation method and application thereof.
[0036] Example 1
[0037] A method for preparing a PDE4 negative allosteric modulator (LS21013A-06), which uses 2-(3-bromo-4-hydroxyphenyl)acetonitrile as a starting material and is obtained through difluoromethylation of the oxygen on the phenolic hydroxyl group, Suzuki coupling, [3+2] cycloaddition reaction, NH alkylation reaction of tetrazole, and hydrolysis of tert-butyl ester.
[0038] As shown in reaction formula II, the process specifically comprises the following steps:
[0039]
[0040] S01: Synthesis of 2-(3-bromo-4-(difluoromethoxy)phenyl)acetonitrile [Intermediate 1]: In a 250mL round-bottom flask, the starting materials 2-(3-bromo-4-hydroxyphenyl)acetonitrile (18mmol, 1.0 equivalent), diethyl (bromodifluoromethyl)phosphonate (27mmol, 1.5 equivalent), potassium carbonate (27mmol, 1.5 equivalent) and 100mL acetonitrile were added; after heating to 80°C and refluxed for 24h, the reaction solution was poured into water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product, which was purified by rapid silica gel chromatography using ethyl acetate / petroleum ether = 1:10 (V / V) as the eluent to obtain Intermediate 1 (white solid, yield 82%);
[0041] S02: Synthesis of 2-(3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)acetonitrile [Intermediate 2]: In a 150mL Schlenk reaction bottle, add Intermediate 1 (10mmol, 1.0 equivalent), 3-chlorophenylboronic acid (15mmol, 1.5 equivalent), potassium carbonate (15mmol, 1.5 equivalent), tetrakistriphenylphosphine palladium (0.5mmol, 0.05 equivalent) and 25mL of a 5:1 mixed solution of toluene and water; after reacting at 105°C under nitrogen protection for 24h, pour the reaction solution into water, extract with ethyl acetate, wash with saturated brine, dry with anhydrous sodium sulfate, and evaporate the solvent under reduced pressure to obtain a crude product, which is purified by rapid silica gel chromatography with ethyl acetate / petroleum ether = 1:5 (V / V) as the eluent to obtain Intermediate 2 (white solid, yield 85%);
[0042] S03: Synthesis of 5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazole [Intermediate 3]: Add intermediate 2 (5mmol, 1.0 equivalent), trimethylsilyl azide (7.5mmol, 1.5 equivalent) and 15mL N,N-dimethylformamide to a 100mL round-bottom flask. After heating to 100℃ for 24h, cool to room temperature and add tetrabutylammonium fluoride (7.5mmol, 1.5 equivalent) and continue stirring at room temperature for 2h; after the reaction is completed, pour the reaction solution into water, extract with ethyl acetate, wash with saturated brine, dry with anhydrous sodium sulfate, and evaporate the solvent under reduced pressure to obtain a crude product. The crude product is purified by rapid silica gel chromatography with ethyl acetate / petroleum ether = 1:2 (V / V) as the eluent to obtain intermediate 3 (white solid, yield 80%);
[0043] S04: Synthesis of tert-butyl 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazolyl-1-yl)acetate [Intermediate 4]: In a 50 mL round-bottom flask, intermediate 3 (4 mmol, 1.0 equivalent), tert-butyl bromoacetate (6 mmol, 1.5 equivalent), potassium carbonate (6 mmol, 1.5 equivalent) and 10 mL N,N-dimethylformamide were added; after reacting at room temperature for 24 h, the reaction solution was poured into water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product, which was purified by rapid silica gel chromatography using ethyl acetate / petroleum ether = 1:5 (V / V) as the eluent to obtain intermediate 4 (white solid, yield 92%);
[0044] S05: Synthesis of 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazolyl-1-yl)acetic acid [LS21013A-06]: In a 10 mL round-bottom flask, intermediate 4 (3 mmol, 1.0 equivalent), formic acid (6 mmol, 2 equivalents) and 10 mL of a 4:1 mixed solution of tert-butyl alcohol and water were added. After reacting at 100°C for 24 hours, the reaction solution was poured into water, diluted hydrochloric acid was added to adjust the pH to 1, and then extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a crude product. The crude product was purified by rapid silica gel chromatography with methanol / dichloromethane = 1:15 (V / V) as the eluent to obtain a PDE4 negative allosteric modulator (LS21013A-06) (white solid, yield 93%).
[0045] The structure of the prepared PDE4 negative allosteric modulator (LS21013A-06) was identified by H-NMR, HPLC and LC-MS. The structural identification results are as follows: Figure 1 , Figure 2 and Figure 3 As shown, the LC-MS detection results showed that the molecular weight was 395.1. The structural identification results showed that the prepared product was 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazolyl-1-yl)acetic acid, that is, a PDE4 negative allosteric modulator (LS21013A-06).
[0046] Molecular docking diagram of PDE4 negative allosteric modulator (LS21013A-06) and PDE4D Figure 4 and Figure 5As shown in the figure, the docking diagram shows that the PDE4 negative allosteric modulator (LS21013A-06) and the PDE4D molecule can be completely docked in theory. Further, the molecular docking diagram of another currently known PDE4 negative allosteric modulator BPN14770 and the prepared PDE4 negative allosteric modulator (LS21013A-06) with PDE4D is shown in the figure below: Figure 6 As shown (where light blue is the molecular structure of BPN14770), it can be seen that the prepared PDE4 negative allosteric modulator (LS21013A-06) has a high overlap area with BPN14770, and the spatial orientation and distance of LS21013A-06 are similar to those of BPN14770.
[0047] In order to investigate the toxicity of LS21013A-06, the MTT colorimetric method was used to detect cell survival and growth. The detection principle is that exogenous MTT can be reduced to water-insoluble blue-purple crystalline formazan by succinate dehydrogenase in the mitochondria of living cells, while dead cells do not have this function. Dimethyl sulfoxide (DMSO) can dissolve the formazan in cells, and its light absorption value is measured at a wavelength of 570nm using an enzyme-linked immunosorbent assay, which can indirectly reflect the number of living cells.
[0048] BV2 cells were plated into 96-well plates so that the number of cells per well was 3 × 10 3 After the cells adhere to the wall, add the corresponding concentration of LS21013A-06 solution (2.5μM, 5μM, 10μM, 20μM, 40μM) prepared by DMEM culture medium along the wall of the well, and then place it in a carbon dioxide incubator for 24h. After 24h, add 150μl of MTT working solution to each well of the well plate, incubate it in an incubator for 4h, and then collect the plate. When collecting the plate, first suck away the culture medium in the well and discard it, then add 150μl of DMSO to each well, shake it on a vibrator for 10min, and use an enzyme reader to detect the absorbance value at a wavelength of 570nm. The calculation method is: cell viability (%) = (absorbance value of the drug group / absorbance value of the control group) × 100%.
[0049] MTT test results Figure 7 As shown, LS21013A-06 (abbreviated as A-06) had no significant effect on the survival rate of BV2 cells at concentrations of 2.5 μM, 5 μM, 10 μM, 20 μM, and 40 μM.
[0050] In vitro, LS21013A-06 was found to be able to counteract the inflammatory response of BV2 cells induced by LPS stimulation. The central nervous system inflammation model in vivo was established by intracerebroventricular injection of LPS into mice to further investigate the anti-inflammatory effect of A-06 in vivo; the effect of LS21013A-06 (abbreviated as A-06) on the activation of hippocampal microglia in LPS model mice was detected. The method of immunofluorescence staining of mouse hippocampus is as follows: the mouse is anesthetized by intraperitoneal injection of 0.3% sodium pentobarbital solution and then the heart is perfused with 4% paraformaldehyde. After perfusion, the mouse brain is carefully removed and placed in a labeled 10ml EP tube containing 4% paraformaldehyde, and placed in a 4°C refrigerator for fixation for 1 day. The fixed mouse brain is placed in 20% and 30% sucrose solutions for dehydration in turn, and when the tissue is completely sunk to the bottom, it can be embedded with OCT cryoembedding agent. After embedding, slice the slices using a freezing microtome. The sliced brain slices were first permeabilized with 0.3% Triton-X 100, and then blocked with 5% goat serum blocking solution at room temperature for 1.5 hours. Then, the primary antibody of iba1 or CD68 was added for overnight incubation. The next day, the fluorescent secondary antibody was added and incubated at room temperature in the dark for 2 hours. Finally, the brain slices were transferred to a glass slide and observed and photographed using an inverted confocal fluorescence microscope.
[0051] The immunofluorescence staining results of LS21013A-06 (abbreviated as A-06) on the activation of hippocampal microglia in LPS model mice showed that ( Figure 8 ), LPS lateral ventricular injection can activate microglia in the mouse hippocampus, and microglial activation is reduced after administration of A-06. CD68 is a lysosomal protein that is expressed at a high level in activated microglia and at a low level in resting microglia. Similarly, immunofluorescence staining showed that ( Fig. 9 ), the expression of CD68 in hippocampal microglia in the LPS model group increased, and the expression of CD68 could be reduced after administration of A-06.
[0052] U343TMZ cells were used to detect the inhibitory rate of PDE4 by enzymes of the prepared LS21013A-06, BPN14770, rolipram and isobutinester at a maximum concentration of 100 (uM). The test results are shown in Table 1:
[0053] Table 1 Detection of the inhibition rate of PDE4
[0054] Compound Inhibition rate (%) <![CDATA[IC 50 (μM)]]> 95%(CI)(μM) LS21013A-06 34% 93.31 36.19-290.9 BPN14770 25% >100 rolipram 21% 322.1 180.1-796.4 Isobuterol 40% 137.5 110.9-173.2
[0055] U343TMZ cells, highest concentration 100 (uM).
[0056] Furthermore, the prepared LS21013A-06 was subjected to enzymatic screening for PDE4Cat, PDE4B1, PDE4B2, PDE4D2, PDE4D3, and PDE4D7. The results are shown in Table 2.
[0057] Table 2 LS21013A-06 was screened by enzymes
[0058]
[0059] SAR analysis of the enzyme activity of PDE4 negative allosteric regulators. For PDE4 negative allosteric regulators, judging from the R1 structure, the R1 of LS21013A-06 is difluoromethyl compared to methyl, and the inhibitor activity of difluoromethyl compared to methyl is about 4 to 8 times better; the X atom is a chlorine atom relative to a fluorine atom, which has better activity not only against PDE4B but also against PDE4D enzymes. Its 1,5-disubstituted and 2,5-disubstituted compounds have good enzyme inhibitory activity. From the simulation docking, it may be because the tetranitrogen ring introduces additional hydrogen bonding with PDE4 molecules.
[0060] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:
[0061] The present invention prepares a PDE4 negative allosteric modulator, preferably 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetic acid (i.e. LS21013A-06), which has the effect of a negative allosteric modulator of PDE4D through detection and can be used in antidepressant drugs, drugs for treating fragile X syndrome and drugs for treating Alzheimer's disease through performance testing.
[0062] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A PDE4 negative allosteric modulator, characterized in that: Its structural formula is shown in Formula I: Wherein, X is one of the halogen elements; R1 is at least one of CH3, H, CHF2 or CH2CH3 groups; R2 is at least one of OH, NH2, NH-IPA, NH-Ethanol, NH-SIPA, NH-S2IPA, NH-OH or NH-R2IPA groups.
2. The PDE4 negative allosteric modulator according to claim 1, characterized in that: The X is Cl, the R1 is CHF2, and the R2 is OH.
3. The method for preparing the PDE4 negative allosteric modulator according to claim 1, characterized in that: The following steps are involved: It is prepared from 2-(3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)acetonitrile via [3+2] cycloaddition reaction, NH alkylation reaction of tetrazole, and hydrolysis of tert-butyl ester.
4. The method for preparing the PDE4 negative allosteric modulator according to claim 2, characterized in that: The following steps are involved: S01: Synthesis of 5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazole: 5 mmol of 2-(3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)acetonitrile, 7.5 mmol of trimethylsilyl azide and 15 mL of N,N-dimethylformamide were mixed, heated to 90-110°C for 18-24 hours, cooled to room temperature, added with 7.5 mmol of tetrabutylammonium fluoride and stirred at room temperature; after the reaction was completed, 5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazole was obtained by extraction, washing, drying, decompression evaporation of the solvent and chromatography purification; S02: Synthesis of tert-butyl 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetate: 4 mmol of 5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetate, 6 mmol of tert-butyl bromoacetate, 6 mmol of potassium carbonate and 10 mL of N,N-dimethylformamide were mixed. After the reaction, the mixture was extracted, washed, dried, the solvent was evaporated under reduced pressure and purified by chromatography to obtain tert-butyl 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetate. S03: Synthesis of 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetic acid: 3 mmol of tert-butyl 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetic acid, 6 mmol of formic acid and 10 mL of tert-butanol and water in a ratio of 4:1 were mixed to obtain a mixed solution. After the reaction and pH adjustment, extraction, washing, drying, solvent removal under reduced pressure and chromatography purification were performed to obtain the PDE4 negative allosteric modulator 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetic acid.
5. The method for preparing a PDE4 negative allosteric modulator according to claim 4, characterized in that: In step S01, the extraction, washing, drying, decompression evaporation of the solvent and chromatography purification are specifically: extraction with ethyl acetate, washing with saturated brine, drying with anhydrous sodium sulfate, and decompression evaporation of the solvent to obtain a crude product, and the crude product is purified by rapid silica gel chromatography using ethyl acetate / petroleum ether = 1:2 (V / V) as an eluent to obtain 5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazole.
6. The method for preparing a PDE4 negative allosteric modulator according to claim 4, characterized in that: In step S02, after the reaction, extraction, washing, drying, solvent evaporation under reduced pressure, and chromatography purification are performed. Specifically, after reacting at room temperature for 24 hours, the reaction solution is poured into water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is evaporated under reduced pressure to obtain a crude product. The crude product is purified by rapid silica gel chromatography using ethyl acetate / petroleum ether = 1:5 (V / V) as an eluent to obtain tert-butyl 2-(5-((3'-chloro-6-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)-1H-tetrazol-1-yl)acetate.
7. The method for preparing a PDE4 negative allosteric modulator according to claim 4, characterized in that: In step S03, after the reaction and pH adjustment, extraction, washing, drying, solvent evaporation under reduced pressure, and chromatography purification are performed. Specifically, after reacting at 100° C. for 24 hours, the reaction solution is poured into water, diluted hydrochloric acid is added to adjust the pH to 1, extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is evaporated under reduced pressure to obtain a crude product. The crude product is purified by rapid silica gel chromatography using methanol / dichloromethane = 1:15 (V / V) as an eluent to obtain a PDE4 negative allosteric modulator.
8. Use of the PDE4 negative allosteric modulator according to claim 1 or 2 in antidepressants, drugs for treating fragile X syndrome and drugs for treating Alzheimer's disease.
Citation Information
Patent Citations
Novel soft PDE4 inhibitors
CN103748073A
Tetrazole-substituted pyrazolopyrimidine inhibitors of JAK kinases and uses thereof
CN114026096A
Substituted oxazole derivative and application thereof in medicine
CN116354931A
PDE4 inhibitor and application thereof in medicine
CN116354992A
